Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | INSR | P06213 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.51 |
| ▸ | YES1 | P07947 | 2/20 | 0.51 |
| ▸ | LYN | P07948 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | ROS1 | P08922 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14660127 | 0.89 | CD274 (0.57) | HCKBTKCD274JAK2FGFR1 | |
| SCHEMBL373634 | 0.87 | HCK (0.56) | HCKBTKCD274JAK2FGFR1 | |
| SCHEMBL4947981 | 0.86 | HCK (0.51) | HCKBTKCD274JAK2FGFR1 | |
| SCHEMBL19848775 | 0.85 | HCK (0.55) | HCKBTKCD274JAK2FGFR1 | |
| SCHEMBL374385 | 0.85 | EGFR (0.64) | CD274JAK2FGFR3LCKADRA2A | |
| SCHEMBL374474 | 0.85 | METTL3 (0.47) | HCKBTKCD274JAK2FGFR1 | |
| SCHEMBL4950163 | 0.84 | KDM1A (0.56) | HCKBTKCD274JAK2FYN | |
| SCHEMBL4947956 | 0.84 | KIT (0.46) | HCKBTKJAK2FGFR1FGFR2 | |
| SCHEMBL19338069 | 0.84 | LCK (0.60) | HCKBTKCD274JAK2FGFR1 | |
| SCHEMBL374409 | 0.83 | CD274 (0.59) | CD274JAK2ABL1LCKTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | claimed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | claimed |
| WO-2024093681-A1 | USE OF INFIGRATINIB IN TREATING GASTRIC CANCER AND ADENOCARCINOMA | QED医药股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-117982507-A | Use of inflictinib in the treatment of gastric and adenocarcinoma | QED医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | CALCILYTIX THERAPEUTICS INC. | 2024-01-11 | — | — | US | disclosed |
| CN-116887822-A | Method for treating achondroplasia | 奎德治疗学股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-114207151-A | Method for treating cancer of urinary system | QED医药股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114144180-A | Method for treating bile duct cancer | QED医药股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111269186-A | Crystalline forms of kinase inhibitors and salts thereof | 诺华股份有限公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-111100077-A | Crystalline forms of 3- (2, 6-dichloro-3, 5-dimethoxy-phenyl) -1- {6- [4- (4-ethyl-piperazin-1-yl) -phenylamino ] -pyrimidin-4-yl } -1-methyl-urea and salts thereof | 诺华股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2011071821-A1 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF. | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071821-A1 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF. | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| CN-101035769-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | FGFR3, FGF2, FGF1 | HCK 2844/4885BTK 2953/4885CD274 4878/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | HCK 339/4885BTK 49/4885CD274 3917/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | HCK 339/4885BTK 49/4885CD274 3917/4885 |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | HCK 1180/4885BTK 269/4885CD274 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.